ANNOUNCEMENT

MedCity CONVERGE July 9-10 in Philly gathers payers, providers, medtech, pharma, digital health, policymakers & more.

Topic: BMY

Amylin acquisition marks new chapter in Bristol-Myers Squibb, AstraZeneca diabetes alliance

Amylin acquisition marks new chapter in Bristol-Myers Squibb, AstraZeneca diabetes alliance

July 2, 2012 8:45 am by | 0 Comments

Bristol-Myers Squibb’s (NYSE:BMY) $7 billion acquisition of Amylin Phramaceuticals (NASDAQGS:AMLN) is one of the largest diabetes deals for the year to date. Given Bristol-Myers Squibb’s and AstraZeneca’s (NYSE:AZN) five-year-old diabetes ... Read more
Bristol-Myers, Sanofi blockbuster drug Plavix topples over patent cliff

Bristol-Myers, Sanofi blockbuster drug Plavix topples over patent cliff

May 17, 2012 6:35 pm by | 0 Comments

Bristol-Myers Squibb (NYSE:BMY) and Sanofi (NYSE:SNY) bid goodbye to their exclusive patent for blockbuster drug Plavix with the U.S. Food and Drug Administration’s approval of generic versions of the blood-thinning ... Read more
Epidural injections of steroids for back pain under review by FDA

Epidural injections of steroids for back pain under review by FDA

January 25, 2012 4:02 pm by | 3 Comments

The U.S. Food and Drug Administration is reviewing epidural injections of steroids to treat neck and back pain following a warning by Bristol-Myers Squibb (NYSE:BMY) seven months ago that administering ... Read more
FDA rejects diabetes drug from Bristol-Myers Squibb, AstraZeneca

FDA rejects diabetes drug from Bristol-Myers Squibb, AstraZeneca

January 19, 2012 8:58 am by | 0 Comments

Bristol-Myers Squibb (NYSE:BMY) and AstraZeneca’s (NYSE:AZN) jointly developed treatment for type 2 diabetes has been turned down by U.S. regulators until lingering questions over the diabetes drug’s benefits and risks ... Read more